Provided by Tiger Fintech (Singapore) Pte. Ltd.

Relay Therapeutics

3.36
+0.12003.70%
Post-market: 3.20-0.1597-4.75%19:41 EDT
Volume:1.77M
Turnover:5.95M
Market Cap:576.06M
PE:-1.54
High:3.45
Open:3.30
Low:3.28
Close:3.24
Loading ...

Relay Therapeutics, Inc. (RLAY): A Bull Case Theory

Insider Monkey
·
14 Dec 2024

TD Cowen Reaffirms Their Buy Rating on Relay Therapeutics (RLAY)

TIPRANKS
·
12 Dec 2024

Relay Therapeutics (RLAY) Gets a Buy from Barclays

TIPRANKS
·
12 Dec 2024

Relay Therapeutics’ RLY-2608: Promising Data and Strategic Plans Reinforce Buy Rating

TIPRANKS
·
12 Dec 2024

Relay Therapeutics Shares up 9.4% After Co Reports Interim Data for Breast Cancer Drug

THOMSON REUTERS
·
11 Dec 2024

Relay Therapeutics Says RLY-2608 With Fulvestrant Data Shows 'Clinically Meaninful' Metastatic Breast Cancer Survival

MT Newswires Live
·
11 Dec 2024

Relay Therapeutics Reports Promising Data on RLY-2608

TIPRANKS
·
11 Dec 2024

BUZZ-Relay Therapeutics rises on interim data for cancer drug

Reuters
·
11 Dec 2024

Relay Therapeutics Shares up 7.5% Premarket After Co Reports Interim Data for Breast Cancer Drug

THOMSON REUTERS
·
11 Dec 2024

Relay Therapeutics reports updated interim clinical data for RLY-2608

TIPRANKS
·
11 Dec 2024

Relay Therapeutics Announces Updated Interim Data for Rly-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

THOMSON REUTERS
·
11 Dec 2024

Relay Therapeutics Inc: 39% Confirmed Orr Across All Patients & 67% in Patients With Kinase Mutations at Rp2d

THOMSON REUTERS
·
11 Dec 2024

Relay Therapeutics Inc -Data Support Planned Initiation of 2L Pivotal Study in 2025

THOMSON REUTERS
·
11 Dec 2024

Relay Therapeutics Inc: Data Support Planned Initiation of 2L Pivotal Study in 2025

THOMSON REUTERS
·
11 Dec 2024

Relay Therapeutics-New Interim Data Show 11.4-Month Median Pfs in 2L Patients With Pi3kΑ-Mutated, Hr+/Her2- Metastatic Breast Cancer at Rp2d

THOMSON REUTERS
·
11 Dec 2024